Among the 928 study participants who reported their post-vaccination symptoms, had received at least two vaccine shots and submitted a dried blood spot, “systemic symptoms were associated with greater antibody response,” the researchers wrote.
After either COVID-19 vaccine dose, 12 percent of study participants reported local symptoms, which includes temporary reactions such as injection site pain, while 48 percent self-reported systemic side effects.
Women, younger age groups and patients who received a Moderna vaccine were associated with a better antibody response, but factors such as race, BMI and underlying conditions were not. Because of this variability, and because the average age was 65 and most of the participants werewhite, the researchers concluded more research between symptoms and vaccine effectiveness is required.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.